摘要
目的:探讨沙利度胺治疗难治性克罗恩病(Crohn's Disease,CD)患者的效果及对疾病活动度、炎性反应及免疫失衡的影响。方法:将我院2018年9月至2020年9月期间91例难治性CD患者按照计算机分组法分为对照组45例,给予常规药物治疗,观察组46例在对照组基础上给予沙利度胺治疗,观察两组临床疗效、炎性反应、免疫失衡情况、疾病活动度以及不良反应。结果:治疗后,观察组总有效率(86.96%)高于对照组(60.00%)(P<0.05);观察组C反应蛋白(C-Reactive Protein,CRP)、白细胞介素-8(Interleukin 8,IL-8)、白细胞计数(White Blood Cell Count,WBC)以及红细胞沉降率(Erythrocyte Sedimentation Rate,ESR)水平均低于对照组(P<0.05);观察组CD3^(+)、CD4^(+)、Th17/Treg水平均低于对照组,CD8^(+)水平高于对照组(P<0.05);观察组一般情况、腹痛、腹部包块、腹泻评分均低于对照组(P<0.05);观察组不良反应发生率(13.04%)与对照组(8.88%)比较差异无统计学意义(P>0.05)。结论:沙利度胺治疗难治性CD患者可减轻炎性反应,调节免疫失衡以及降低疾病活动度,进而提高治疗效果,且不增加不良反应。
Objective:To explore the effect of thalidomide in the treatment of patients with refractory Crohn's Disease(CD)and its influence on disease activity,inflammatory response and immune imbalance.Methods:The 91 patients with refractory CD in our hospital from September 2018 to September 2020 were divided into a control group of 45 patients according to the computerized grouping method,and they were given conventional drug treatment,and 46 patients in the observation group were given thalidomide on the basis of the control group.In the treatment of dosamine,the clinical efficacy,inflammatory response,immune imbalance,disease activity and adverse reactions were observed in the two groups.Results:After treatment,the total effective rate of the observation group(86.96%)was higher than that of the control group(60.00%)(P<0.05);Observation group C-Reactive Protein(CRP),Interleukin 8(IL-8),White Blood Cell Count(WBC)and Erythrocyte Sedimentation Rate(ESR)levels Are lower than the control group(P<0.05);The levels of CD3^(+),CD4^(+),Th17/Treg in the observation group were lower than those in the control group,and the level of CD8^(+)was higher than that in the control group(P<0.05);the general condition,abdominal pain,abdominal mass,and diarrhea scores of the observation group were lower than those of the control group(P<0.05);There was no significant difference in the incidence of adverse reactions between the observation group(13.04%)and the control group(8.88%)(P>0.05).Conclusions:Thalidomide in the treatment of refractory CD patients can reduce inflammatory reaction,regulate immune imbalance and reduce disease activity,so as to improve the treatment effect without increasing adverse reactions.
作者
耿同磊
袁慧敏
刘欣
杨鹤
Geng Tong-lei;Yuan Hui-min;Liu Xin;Yang He(Department of Gastroenterology,Jun County People's Hospital,Jun County 456250,Henan,China;Department of Gastroenterology,Hebi People's Hospital,Hebi 458030,Henan,China;Department of Integrated Traditional Chinese and Western Medicine,Hebi People's Hospital,Hebi 458030,Henan,China)
出处
《四川生理科学杂志》
2021年第10期1706-1709,共4页
Sichuan Journal of Physiological Sciences
关键词
沙利度胺
难治性克罗恩病
疾病活动度
炎性反应
免疫失衡
Thalidomide
Refractory Crohn's Disease
Disease activity
Inflammatory response
Immune imbalance
